FAWZIA HASAN: Open Payments
NPI 1467506915 · WILMINGTON, DE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$438 in 6 payments from 5 companies in 2025. Trend: 2023 $173 · 2024 $273 · 2025 $438
Food & beverage: $438
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 1 | $132 |
| Vanda Pharmaceuticals Inc. | 1 | $125 |
| Axsome Therapeutics, Inc. | 1 | $120 |
| Supernus Pharmaceuticals, Inc. | 2 | $32 |
| ABBVIE INC. | 1 | $28 |
Products named: INGREZZA, FANAPT, Auvelity, Qelbree, VRAYLAR.
Industry payments across DE — which companies pay providers there.
